Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
APYX
Apyx Medical IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$128.90M
P/E Ratio
—
EPS
$-0.20
Beta
1.35
52W High
$5.08
52W Low
$1.70
50-Day MA
$4.15
200-Day MA
$3.85
Dividend Yield
—
Profit Margin
-14.80%
Forward P/E
72.46
PEG Ratio
0.59
About Apyx Medical Inc
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.
Fundamentals
| Revenue (TTM) | $58.41M |
| Gross Profit (TTM) | $37.09M |
| EBITDA | $-2.75M |
| Operating Margin | -13.00% |
| Return on Equity | -90.70% |
| Return on Assets | -3.71% |
| Revenue/Share (TTM) | $1.37 |
| Book Value | $0.25 |
| Price-to-Book | 11.97 |
| Price-to-Sales (TTM) | 2.21 |
| EV/Revenue | 2.391 |
| EV/EBITDA | -5.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 22.10% |
| Shares Outstanding | $42.12M |
| Float | $30.50M |
| % Insiders | 13.55% |
| % Institutions | 50.53% |
Historical Volatility
HV 10-Day
101.03%
HV 20-Day
82.61%
HV 30-Day
75.04%
HV 60-Day
79.58%
HV Rank
43.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.60 target)
1
Strong Buy4
BuyLatest News
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its second quarter ended June 30, 2026.
GlobeNewsWire8/6/2026Neutral
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA.
GlobeNewsWire7/28/2026Neutral
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CLEARWATER, Fla., July 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the second quarter of fiscal year 2026 will be released after markets close on Thursday, August 6th.
GlobeNewsWire7/23/2026Neutral
Body by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the Runway
CLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), will return to Miami Swim Week with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations.
PRNewsWire5/27/2026Neutral
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach Published data demonstrates visible reduction in dimpling and progressive tissue remodeling through a single-session approach
GlobeNewsWire5/21/2026Neutral
Apyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with Liposuction
CLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open 1.
GlobeNewsWire5/14/2026Neutral
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON Addition of the power liposuction capability as a second advanced liposuction modality is expected to drive even greater market demand for AYON
GlobeNewsWire5/11/2026Neutral
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026.
GlobeNewsWire5/7/2026Neutral
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th.
GlobeNewsWire4/23/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on APYX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026